Arcturus Therapeutics Holdings Inc. (ARCT) — SEC Financial Statements & Analysis

Arcturus Therapeutics Holdings Inc. (ARCT) is a pharmaceutical preparations company, incorporated in DE. Arcturus Therapeutics Holdings Inc. trades on Nasdaq as: ARCT. Arcturus Therapeutics Holdings Inc. (ARCT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Arcturus Therapeutics Holdings Inc. carries a market cap of $191.00M, a P/E ratio of -2.05x, a P/B ratio of 1.11x, a P/S ratio of 6.50x, an enterprise value of $-2.51M, and an EV/EBITDA multiple of 0.03x. On profitability, it posts an operating margin of -348.32%, a net margin of -317.61%, a Return on Equity (ROE) of -46.31%, and a Return on Assets (ROA) of -34.96%. Per share, it reports EPS of $-3.28, diluted EPS of $-3.28, free cash flow per share of $-2.57, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -75.95% year-over-year, net income growth of 55.04% year-over-year, and EPS growth of 47.98% year-over-year. On the balance sheet, it maintains a current ratio of 5.88x, a quick ratio of 5.88x, working capital of $163.63M, a debt-to-equity ratio of 0.31x, a debt ratio of 0.23, free cash flow of $-73.00M (TTM), and net debt of $-193.51M. Figures sourced from SEC EDGAR.

Market Cap

$191.00M

P/E TTM

-2.05x

EPS TTM

$-3.28

P/B TTM

1.11x

ROE TTM

-46.31%

ROA TTM

-34.96%

Debt To Equity

0.31x

Free Cash Flow TTM

$-73.00M

Net Revenue TTM Growth 1Y

-75.95%

Data as of 2026-06-30 · Source: SEC EDGAR